Genflow Biosciences Plc recently announced the international publication of its Patent Cooperation Treaty (PCT) application, WO 2026/062177 A1, marking a significant milestone in the company’s expanding intellectual property portfolio focused on innovative therapies for age-related conditions.

The published patent application outlines novel variants of Sirtuin 6 (SIRT6), a protein widely studied for its role in cellular health, longevity, and metabolic regulation. Genflow’s proprietary approach targets the prevention and treatment of muscular diseases, with particular emphasis on Frailty syndrome and Sarcopenia, two major contributors to declining physical function in aging populations.

According to the company, the application describes a comprehensive suite of therapeutic strategies, including compositions and methods involving nucleic acids, engineered polypeptides, delivery vectors, and pharmaceutical formulations. These innovations are designed to address muscle mass loss and disruptions in muscle endocrine function, both of which are hallmarks of age-associated muscular degeneration.

“The publication of this PCT application represents an important step in broadening our intellectual property estate beyond longevity and metabolic indications,” the company stated. “It reinforces our commitment to developing transformative therapies that target the biological mechanisms of aging and muscle decline.”

A key component of Genflow’s pipeline is its lead program, GF-1002, a gene therapy candidate that delivers a centenarian-derived variant of SIRT6. This approach is intended to replicate genetic traits associated with exceptional longevity and improved physiological resilience. The company reported that a proof-of-concept clinical trial in aged dogs was initiated in March 2025, providing early translational insights into the therapy’s potential efficacy and safety.

The international publication of this patent application preserves Genflow’s ability to pursue patent protection across multiple global jurisdictions, supporting future commercialization and strategic partnerships.

Founded in 2020, Genflow Biosciences is headquartered in the United Kingdom, with research and development operations in Belgium. The company continues to position itself at the forefront of longevity-focused biotechnology, leveraging advanced gene therapy platforms to address unmet medical needs associated with aging.

This latest development underscores Genflow’s broader strategy to strengthen its scientific platform while enabling new development pathways and collaborative opportunities within the global biotech ecosystem.